Advertisement

Topics

NASH: KOL Insight [2017] [Report Updated: 01062017] Prices from USD $8795

05:29 EDT 1 Jul 2017 | BioPortfolio Report Blog

Will novel therapies revolutionise the treatment of NASH?



No drug therapies have been approved for patients with nonalcoholic steatohepatitis NASH but how is this set to change within the next five years? Allergan/Tobira's cenicriviroc and Gilead's selonsertib have entered the Phase III pipeline but how do they compare with other agents, Intercept's obeticholic acid and Genfit's elafibranor. How important are improvements in fibrosis and what do key opinion leaders KOLs believe will impact drug approval prospects? Experts discuss current study designs and endpoints and the challenges facing novel therapies such as longterm safety, cost and diagnosis.



Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Nonalcoholic steatohepatitis NASH. 6 US and 6 European KOLs give their insight on two offlabel marketed products and 12 pipeline programmes. KOLs also provide their candid views on the potential for novel mechanisms of action.








Take a tour of the report now:



The table of contents >
The key business questions answered >
The key KOL quotes >
See the therapies covered >
Find out who the 6 EU 6 US KOLs are >
Review an extract from the report 1 drug profile >

Top Takeaways



Obeticholic acid approved for primary biliary cirrhosis PBC but what are its prospects in NASH? Find out how KOLs view the modifications of the pivotal Phase III REGENERATE study and whether they are concerned about longterm safety and cost?
Cenicriviroc and selonsertib have entered Phase III development but what are KOL expectations? Both drugs have demonstrated improvements in fibrosis in Phase II studies but what do the experts think about potential future outcomes?
Does elafibranor have potential for broad use in NASH? The Phase III RESOLVEIT Phase III study is ongoing with Genfit's elafibranor but how do KOLs view the study design?
Emricasan and Aramchol are targeting different stages of NASH but which strategies are most appealing? Find out KOL opinions on different approaches targeting the multifaceted disease.
Which earlystage mechanisms of action MOAs show the most promise? Pipeline drugs with diverse mechanisms are in Phase II. Given the complexities of NASH pathogenesis, which MOAs are the most appealing to KOLs?
Which clinical endpoints are key to securing drug approval in NASH? Are improvements in fibrosis crucial or are KOLs satisfied with other endpoints such as resolution of NASH, NAFLD activity score NAS and hepatic venous pressure gradient HVPG?
Clinical trial enrolment and design an issue going forward? Companies have announced reductions in patient enrolment numbers in NASH clinical trials due to challenges encountered. Do KOLs have concerns about trial enrolment?
Noninvasive biomarkers a critical unmet need in NASH? Liver biopsy remains the gold standard for NASH diagnosis. Are KOLs concerned about the requirement of liver biopsies to monitor drug response and disease progression in clinical trials?
Are combination approaches the key to successfully treating NASH? Given the multitude of pathways involved in the pathogenesis of NASH, do KOLs agree that future treatment is most likely going to involve combination therapy?
Will cost and reimbursement restraints impact NASH? Costeffectiveness of novel agents approved in NASH is likely to become an important consideration. Explore the concerns voiced by KOLs about the potential restrictions facing novel therapies.

Quotes



Combinations ensure [that] you're not just targeting one pathway. Fibrosis is important but so are the inflammatory cascade, insulin resistance and metabolic syndrome. I think that the most promising will be combinations of a primarily antifibrotic agent with an agent that specifically targets the metabolic pathway and insulin resistance. US Key Opinion Leader



This is very developing field, a lot of labs around the world are looking for the ideal noninvasive biomarker for NASH, and I am quite confident that in the next five years we will discover the best one. EU Key Opinion Leader



Sample of therapies covered



Marketed Therapies offlabel


pioglitazone Actos/Glustin; Takeda/Eli Lilly


vitamin E


Pipeline Therapies


obeticholic acid Ocaliva; Intercept Pharmaceuticals


elafibranor Genfit Pharmaceuticals


cenicriviroc Allergan/Tobira Therapeutics


selonsertib Gilead


emricasan Novartis/Conatus Pharmaceuticals


Aramchol Galmed Pharmaceuticals


semaglutide Novo Nordisk


GRMD02 Galectin Therapeutics


Plus 4 more Download the complete list here >



Sample of KOLs interviewed



KOLs from North America


Professor Scott L. Friedman, MD, Dean for Therapeutic Discovery and Chief of Division of Liver Diseases, The Icahn School of Medicine, Mount Sinai Hospital, New York City


Professor Joel E. Lavine, MD, PhD, Chief of the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Morgan Stanley Children's Hospital and Columbia University Medical Center New York


Dr. Naim Alkhouri, MD, Staff Physician, Digestive Disease Institute and Cleveland Clinic's Children Hospital, Cleveland, Ohio


KOLs from Europe


Professor Vlad Ratziu, MD, PhD, Professor of Hepatology, Universit Pierre et Marie Curie and the Hpital PitiSalptrire Medical School, Paris, France


Professor Dr. Stefano Bellentani, MD, PhD, Gastroenterologist at Azienda USL di Modena, Italy


Professor Phillip Newsome, MD, Professor of Experimental Hepatology, Director of the Centre for Liver Research and Clinical Director of the Birmingham University Stem Cell Centre, UK


Plus 6 more download the full list now >



Money Back Guarantee


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.




About FirstWord



FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.



FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.


FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Original Article: NASH: KOL Insight [2017] [Report Updated: 01062017] Prices from USD $8795

NEXT ARTICLE

More From BioPortfolio on "NASH: KOL Insight [2017] [Report Updated: 01062017] Prices from USD $8795"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...